Literature DB >> 22160793

Reversible progressive supranuclear palsy-like phenotype as an initial manifestation of HIV infection.

Wooyoung Jang1, Joong-Seok Kim, Jin Young Ahn, Hee-Tae Kim.   

Abstract

Movement disorders are common manifestations of human immunodeficiency virus (HIV) infection, and may sometimes be the initial manifestations of HIV infection. Although secondary progressive supranuclear palsy (PSP) due to factors such as paraneoplastic, vascular, and hypoxic-ischemic injury have been reported, PSP associated with HIV infection has received little attention. We describe a patient who displayed a progressive parkinsonian phenotype fulfilling the criteria for PSP over a period of a year. The parkinsonism was the initial manifestation of HIV infection and was eliminated by highly active antiretroviral therapy. This case report indicates that one should consider HIV infection as a cause of PSP-like parkinsonism.

Entities:  

Mesh:

Year:  2011        PMID: 22160793     DOI: 10.1007/s10072-011-0875-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  15 in total

1.  Neuro-ophthalmological disorders in HIV infected subjects with neurological manifestations.

Authors:  J-C Mwanza; L K Nyamabo; T Tylleskär; G T Plant
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

2.  Parkinsonism in hiv-infected patients on highly active antiretroviral therapy.

Authors:  Stephen Tisch; Bruce Brew
Journal:  Neurology       Date:  2009-08-04       Impact factor: 9.910

3.  Parkinsonism and AIDS: a clinical comparative study before and after HAART.

Authors:  Ana Lucia Zuma de Rosso; James Pitágoras de Mattos; Rosalie Branco Correa; Denise Hack Nicaretta; Sérgio Augusto Pereira Novis
Journal:  Arq Neuropsiquiatr       Date:  2009-09       Impact factor: 1.420

Review 4.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  Progressive supranuclear palsy-like phenotype associated with bilateral hypoxic-ischemic striopallidal lesions.

Authors:  Hee Tae Kim; Simon Shields; Kailash P Bhatia; Niall Quinn
Journal:  Mov Disord       Date:  2005-06       Impact factor: 10.338

Review 6.  Paraneoplastic progressive supranuclear palsy syndrome in a patient with B-cell lymphoma.

Authors:  J H Tan; B C Goh; P A Tambyah; E Wilder-Smith
Journal:  Parkinsonism Relat Disord       Date:  2005-05       Impact factor: 4.891

Review 7.  HIV-related movement disorders: epidemiology, pathogenesis and management.

Authors:  Francisco Cardoso
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Parkinsonism with HIV infection.

Authors:  S M Mirsattari; C Power; A Nath
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

Review 9.  Movement disorders and AIDS: a review.

Authors:  Winona Tse; Maria G Cersosimo; Jean-Michel Gracies; Susan Morgello; C Warren Olanow; William Koller
Journal:  Parkinsonism Relat Disord       Date:  2004-08       Impact factor: 4.891

10.  Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection.

Authors:  Negar Khanlou; David J Moore; Gursharan Chana; Mariana Cherner; Deborah Lazzaretto; Sharron Dawes; Igor Grant; Eliezer Masliah; Ian P Everall
Journal:  J Neurovirol       Date:  2009-04       Impact factor: 2.643

View more
  1 in total

Review 1.  Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes-Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism.

Authors:  Patrycja Krzosek; Natalia Madetko; Anna Migda; Bartosz Migda; Dominika Jaguś; Piotr Alster
Journal:  Front Aging Neurosci       Date:  2022-02-09       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.